Luis H. Martín Arias

Luis H. Martín Arias

Auto-generated profile, based on publicly available information

Luis H. Martín Arias

Universidad de Valladolid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2012 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
CTCarlos Treceño
Carlos Treceño
LALuis H. Martín Arias
Luis H. Martín Arias
MSMaría Sainz-Gil
María Sainz-Gil
ISInés Salado
Inés Salado
POPilar García Ortega
Pilar García Ortega
ACAlfonso Carvajal
Alfonso Carvajal

1 January 2006 in Drug Safety
Verified
Journal Article
Closed access
PDF file
ACAlfonso Carvajal
Alfonso Carvajal
DSDiego Macias Saint-Gerons
Diego Macias Saint-Gerons
MSMaría Sainz-Gil
María Sainz-Gil
SOSara Ortega
Sara Ortega
LALuis H. Martín Arias
Luis H. Martín Arias
JMJean-Louis Montastruc
Jean-Louis Montastruc

23 June 2004 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
ACAlfonso Carvajal
Alfonso Carvajal
LALuis H. Martín Arias
Luis H. Martín Arias
EVEva Vega
Eva Vega
JSJosé Antonio García Sánchez
José Antonio García Sánchez
IRIgor Martín Rodríguez
Igor Martín Rodríguez
JPJavier García del Pozo
Javier García del Pozo
There has been an increase of anti-ulcer drug consumption in Spain. A high proportion of this consumption may be due to the use of those drugs as gastroprotective agents when co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs). The aim of this study was to learn how these treatments are being used: the prevalence of use, the type of drug and the main features of patients. A sample of patients going to pharmacies with a NSAID prescription, with or without a gastroprotective agent, was obtained. A survey questionnaire was distributed to learn clinical and demographic data of the patients. Of the 942 patients interviewed, 41.6% were co-treated with a gastroprotective agent in addition to the NSAID. Most of these patients received proton-pump inhibitors and, to a lesser extent, histamine-2-receptor antagonists, antacids and prostaglandin analogues. The use of gastroprotective agents increased with age, treatment duration and illness chronicity; specialists prescribed a higher proportion of those co-treatments than did general practitioners. There was a high prescription rate of gastroprotective agents; in general, these were used according to recommendations. However, the type of gastroprotective agents being used does not seem to be justified by the current guidelines: histamine-2-receptor antagonists and antacid drugs have not proved their efficacy in this indication. The fact that one in four treatments with gastroprotective drugs was issued to patients without associated risk factors identifies a possible problem where an intervention could be appropriate.

1 January 2007 in Drug Safety
Verified
Journal Article
Closed access
PDF file
ACAlfonso Carvajal
Alfonso Carvajal
DSDiego Macias Saint-Gerons
Diego Macias Saint-Gerons
AGAngélica Gutiérrez
Angélica Gutiérrez
SOSara Ortega
Sara Ortega
MSMaría Sainz-Gil
María Sainz-Gil
AVAlfonso Velasco
Alfonso Velasco

21 April 2010 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
LALuis H. Martín Arias
Luis H. Martín Arias
CLCarlos Treceño Lobato
Carlos Treceño Lobato
SOSara Ortega
Sara Ortega
AVAlfonso Velasco
Alfonso Velasco
ACAlfonso Carvajal
Alfonso Carvajal
JPJavier García del Pozo
Javier García del Pozo

22 April 2009 in BMJ
Verified
Journal Article
Closed access
MSMaría Sainz-Gil
María Sainz-Gil
JPJ. G. D. Pozo
J. G. D. Pozo
LALuis H Martín Arias
Luis H Martín Arias
ACAlfonso Carvajal
Alfonso Carvajal